{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,5]],"date-time":"2026-10-05T08:53:48Z","timestamp":1791190428437,"version":"4.1.0"},"reference-count":78,"publisher":"MDPI AG","issue":"19","license":[{"start":{"date-parts":[[2026,10,3]],"date-time":"2026-10-03T00:00:00Z","timestamp":1790985600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["82305350"],"award-info":[{"award-number":["82305350"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"award":["82305350"],"award-info":[{"award-number":["82305350"]}],"id":[{"id":"https:\/\/ror.org\/01h0zpd94","id-type":"ROR","asserted-by":"publisher"}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Cells"],"abstract":"<jats:p>Immune-checkpoint biomarkers in gynecologic cancers primarily estimate antigenic potential or characterize an inhibited immune response. However, they do not establish whether malignant cells are visible to antigen-specific lymphocytes. We define antigen-presentation competence as the capacity of the tumor\u2013immune ecosystem to generate antigenic peptides, display them through functional human leukocyte antigen molecules, prime cognate T cells through professional antigen-presenting cells, and permit recognition of malignant cells by effector lymphocytes. Recurrent defects have been reported at each step in cervical, endometrial, and ovarian cancers, but the evidence is not equally mature across these diseases. Cervical studies emphasize human papillomavirus-associated immune selection and antigen-processing machinery abnormalities; endometrial cancer provides relatively direct treatment-linked evidence for major histocompatibility complex class I and interferon-pathway defects; and ovarian cancer offers direct immunopeptidomic and multiregion evidence that antigen availability, presentation, and immune recognition can diverge. Taken together, the literature makes antigen-presentation competence a testable functional framework. It does not yet justify a biomarker or clinical score. Prospective work will need spatial and longitudinal measurements of tumor presentation, dendritic-cell priming, and T-cell recognition. A key test is whether these measurements improve prediction beyond mismatch repair, polymerase epsilon, programmed death-ligand 1, and tumor mutational burden.<\/jats:p>","DOI":"10.3390\/cells15191809","type":"journal-article","created":{"date-parts":[[2026,10,5]],"date-time":"2026-10-05T08:00:22Z","timestamp":1791187222000},"page":"1809","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Antigen-Presentation Competence in Gynecologic Cancers: Mechanisms, Evidence and Translational Priorities"],"prefix":"10.3390","volume":"15","author":[{"ORCID":"https:\/\/orcid.org\/0009-0006-7120-9321","authenticated-orcid":false,"given":"Zihao","family":"Xu","sequence":"first","affiliation":[{"name":"School of Chinese Medicine, Hubei University of Chinese Medicine, Wuhan 430065, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yifan","family":"Liu","sequence":"additional","affiliation":[{"name":"School of Chinese Medicine, Hubei University of Chinese Medicine, Wuhan 430065, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jun","family":"Xu","sequence":"additional","affiliation":[{"name":"School of Basic Medical Sciences, Hubei University of Chinese Medicine, Wuhan 430065, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mengxin","family":"Xiong","sequence":"additional","affiliation":[{"name":"The First Clinical Medical School, Hubei University of Chinese Medicine, Wuhan 430065, China"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2026,10,3]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"7695","DOI":"10.1038\/s41467-024-52098-8","article-title":"Neoadjuvant immune checkpoint blockade in women with mismatch repair deficient endometrial cancer: A phase I study","volume":"15","author":"Eerkens","year":"2024","journal-title":"Nat. Commun."},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"5294","DOI":"10.1158\/1078-0432.CCR-25-1442","article-title":"The Impact of JAK1 Pathogenic Variants and MHC-I Expression on Response to Immune Checkpoint Inhibition in Endometrial Cancer","volume":"31","author":"Carballo","year":"2025","journal-title":"Clin. Cancer Res."},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"1856","DOI":"10.1056\/NEJMoa2112435","article-title":"Pembrolizumab for Persistent, Recurrent, or Metastatic Cervical Cancer","volume":"385","author":"Colombo","year":"2021","journal-title":"N. Engl. J. Med."},{"key":"ref_4","doi-asserted-by":"crossref","unstructured":"Pizzimenti, C., Fiorentino, V., Pepe, L., Franchina, M., Ruggeri, C., Ercoli, A., Ciappina, G., Berretta, M., Tuccari, G., and Ieni, A. (2025). Predictive Biomarkers for Immunotherapy in Endometrial Carcinoma. Cancers, 17.","DOI":"10.3390\/cancers17152420"},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"e001111","DOI":"10.1136\/jitc-2020-001111","article-title":"Antigen processing and presentation in cancer immunotherapy","volume":"8","author":"Lee","year":"2020","journal-title":"J. Immunother. Cancer"},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"492","DOI":"10.1200\/PO.20.00009","article-title":"Genomic Determinants of De Novo Resistance to Immune Checkpoint Blockade in Mismatch Repair\u2013Deficient Endometrial Cancer","volume":"4","author":"Gulhan","year":"2020","journal-title":"JCO Precis. Oncol."},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"627","DOI":"10.1038\/s41379-020-00682-w","article-title":"MHC class I loss in endometrial carcinoma: A potential resistance mechanism to immune checkpoint inhibition","volume":"34","author":"Friedman","year":"2021","journal-title":"Mod. Pathol."},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"604","DOI":"10.1038\/s41571-023-00789-4","article-title":"Antigen presentation in cancer\u2014Mechanisms and clinical implications for immunotherapy","volume":"20","author":"Yang","year":"2023","journal-title":"Nat. Rev. Clin. Oncol."},{"key":"ref_9","doi-asserted-by":"crossref","unstructured":"Qin, Y., Ekmekcioglu, S., Forget, M.A., Szekvolgyi, L., Hwu, P., Grimm, E.A., Jazaeri, A.A., and Roszik, J. (2017). Cervical Cancer Neoantigen Landscape and Immune Activity is Associated with Human Papillomavirus Master Regulators. Front. Immunol., 8.","DOI":"10.3389\/fimmu.2017.00689"},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"312","DOI":"10.1158\/2159-8290.CD-22-0686","article-title":"Distinct Mechanisms of Mismatch-Repair Deficiency Delineate Two Modes of Response to Anti\u2013PD-1 Immunotherapy in Endometrial Carcinoma","volume":"13","author":"Chow","year":"2023","journal-title":"Cancer Discov."},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"729","DOI":"10.1016\/j.cell.2020.01.026","article-title":"Proteogenomic Characterization of Endometrial Carcinoma","volume":"180","author":"Dou","year":"2020","journal-title":"Cell"},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"E9942","DOI":"10.1073\/pnas.1707658114","article-title":"The immunopeptidomic landscape of ovarian carcinomas","volume":"114","author":"Schuster","year":"2017","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"ref_13","doi-asserted-by":"crossref","unstructured":"The Cancer Genome Atlas Research Network (2017). Integrated genomic and molecular characterization of cervical cancer. Nature, 543, 378\u2013384.","DOI":"10.1038\/nature21386"},{"key":"ref_14","doi-asserted-by":"crossref","unstructured":"Evans, A.M., Salnikov, M., Gameiro, S.F., Maleki Vareki, S., and Mymryk, J.S. (2022). HPV-Positive and -Negative Cervical Cancers Are Immunologically Distinct. J. Clin. Med., 11.","DOI":"10.3390\/jcm11164825"},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"405","DOI":"10.1038\/bjc.1995.346","article-title":"Frequency of down-regulation of individual HLA-A and -B alleles in cervical carcinomas in relation to TAP-1 expression","volume":"72","author":"Keating","year":"1995","journal-title":"Br. J. Cancer"},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"197","DOI":"10.1007\/s00262-007-0362-8","article-title":"Association of antigen processing machinery and HLA class I defects with clinicopathological outcome in cervical carcinoma","volume":"57","author":"Mehta","year":"2008","journal-title":"Cancer Immunol. Immunother."},{"key":"ref_17","first-page":"1211","article-title":"Deficient expression of components of the MHC class I antigen processing machinery in human cervical carcinoma","volume":"19","author":"Ritz","year":"2001","journal-title":"Int. J. Oncol."},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"e15509","DOI":"10.1111\/tan.15509","article-title":"Allelic loss of HLA class I facilitates evasion from immune surveillance in cervical intraepithelial neoplasia","volume":"103","author":"Kawase","year":"2024","journal-title":"HLA"},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"295","DOI":"10.1038\/s41568-023-00560-y","article-title":"Dynamics and specificities of T cells in cancer immunotherapy","volume":"23","author":"Oliveira","year":"2023","journal-title":"Nat. Rev. Cancer"},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"209","DOI":"10.1038\/s41577-021-00574-3","article-title":"CD8+ T cell differentiation and dysfunction in cancer","volume":"22","author":"Philip","year":"2022","journal-title":"Nat. Rev. Immunol."},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"e011948","DOI":"10.1136\/jitc-2025-011948","article-title":"Targeting HK3 in tumor-associated macrophages enhances antitumor immunity through augmenting antigen cross-presentation in cervical cancer","volume":"13","author":"Yang","year":"2025","journal-title":"J. Immunother. Cancer"},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"eads7405","DOI":"10.1126\/sciadv.ads7405","article-title":"Immunogenic cryptic peptides dominate the antigenic landscape of ovarian cancer","volume":"11","author":"Raja","year":"2025","journal-title":"Sci. Adv."},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"195","DOI":"10.1038\/s41541-025-01234-6","article-title":"Proteogenomic approach to immunopeptidomics of ovarian tumors identifies shared peptide vaccine candidates","volume":"10","author":"Chiaro","year":"2025","journal-title":"npj Vaccines"},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"1189","DOI":"10.1007\/s00262-020-02764-9","article-title":"Impact of tumor heterogeneity and microenvironment in identifying neoantigens in a patient with ovarian cancer","volume":"70","author":"Dao","year":"2021","journal-title":"Cancer Immunol. Immunother."},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"818","DOI":"10.1016\/j.cell.2020.09.015","article-title":"Key Parameters of Tumor Epitope Immunogenicity Revealed Through a Consortium Approach Improve Neoantigen Prediction","volume":"183","author":"Wells","year":"2020","journal-title":"Cell"},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"1755","DOI":"10.1016\/j.cell.2018.03.073","article-title":"Interfaces of Malignant and Immunologic Clonal Dynamics in Ovarian Cancer","volume":"173","author":"Zhang","year":"2018","journal-title":"Cell"},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"999","DOI":"10.1007\/s00262-018-2131-2","article-title":"Defective HLA class I antigen processing machinery in cancer","volume":"67","author":"Cai","year":"2018","journal-title":"Cancer Immunol. Immunother."},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"3372","DOI":"10.1158\/1078-0432.CCR-07-4433","article-title":"HLA Class I Antigen Processing Machinery Component Expression and Intratumoral T-Cell Infiltrate as Independent Prognostic Markers in Ovarian Carcinoma","volume":"14","author":"Han","year":"2008","journal-title":"Clin. Cancer Res."},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"6387","DOI":"10.1158\/0008-5472.CAN-06-0029","article-title":"Frequent Loss of HLA-A2 Expression in Metastasizing Ovarian Carcinomas Associated with Genomic Haplotype Loss and HLA-A2-Restricted HER-2\/neu-Specific Immunity","volume":"66","author":"Norell","year":"2006","journal-title":"Cancer Res."},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"711","DOI":"10.1016\/j.ccell.2017.04.003","article-title":"Tumor-Residing Batf3 Dendritic Cells Are Required for Effector T Cell Trafficking and Adoptive T Cell Therapy","volume":"31","author":"Spranger","year":"2017","journal-title":"Cancer Cell"},{"key":"ref_31","doi-asserted-by":"crossref","first-page":"1022","DOI":"10.1016\/j.cell.2018.01.004","article-title":"NK Cells Stimulate Recruitment of cDC1 into the Tumor Microenvironment Promoting Cancer Immune Control","volume":"172","author":"Bonavita","year":"2018","journal-title":"Cell"},{"key":"ref_32","doi-asserted-by":"crossref","first-page":"2338","DOI":"10.1016\/j.immuni.2021.08.026","article-title":"Conventional type I dendritic cells maintain a reservoir of proliferative tumor-antigen specific TCF-1+ CD8+ T cells in tumor-draining lymph nodes","volume":"54","author":"Schenkel","year":"2021","journal-title":"Immunity"},{"key":"ref_33","doi-asserted-by":"crossref","first-page":"139","DOI":"10.1186\/s40425-018-0446-3","article-title":"Mature dendritic cells correlate with favorable immune infiltrate and improved prognosis in ovarian carcinoma patients","volume":"6","author":"Truxova","year":"2018","journal-title":"J. Immunother. Cancer"},{"key":"ref_34","doi-asserted-by":"crossref","first-page":"694","DOI":"10.1126\/science.aat5030","article-title":"WDFY4 is required for cross-presentation in response to viral and tumor antigens","volume":"362","author":"Theisen","year":"2018","journal-title":"Science"},{"key":"ref_35","doi-asserted-by":"crossref","first-page":"4016","DOI":"10.1016\/j.cell.2021.05.021","article-title":"Secreted gelsolin inhibits DNGR-1-dependent cross-presentation and cancer immunity","volume":"184","author":"Giampazolias","year":"2021","journal-title":"Cell"},{"key":"ref_36","doi-asserted-by":"crossref","first-page":"521","DOI":"10.1007\/s00432-003-0463-5","article-title":"Dendritic cell-based tumor vaccine for cervical cancer II: Results of a clinical pilot study in 15 individual patients","volume":"129","author":"Ferrara","year":"2003","journal-title":"J. Cancer Res. Clin. Oncol."},{"key":"ref_37","doi-asserted-by":"crossref","unstructured":"Koeneman, B.J., Schreibelt, G., Gorris, M.A.J., Hins-De Bree, S., Westdorp, H., Ottevanger, P.B., and de Vries, I.J.M. (2024). Dendritic cell vaccination combined with carboplatin\/paclitaxel for metastatic endometrial cancer patients: Results of a phase I\/II trial. Front. Immunol., 15.","DOI":"10.3389\/fimmu.2024.1368103"},{"key":"ref_38","doi-asserted-by":"crossref","unstructured":"Becker, J.P., and Riemer, A.B. (2022). The Importance of Being Presented: Target Validation by Immunopeptidomics for Epitope-Specific Immunotherapies. Front. Immunol., 13.","DOI":"10.3389\/fimmu.2022.883989"},{"key":"ref_39","doi-asserted-by":"crossref","unstructured":"Dhatchinamoorthy, K., Colbert, J.D., and Rock, K.L. (2021). Cancer Immune Evasion Through Loss of MHC Class I Antigen Presentation. Front. Immunol., 12.","DOI":"10.3389\/fimmu.2021.636568"},{"key":"ref_40","doi-asserted-by":"crossref","first-page":"15","DOI":"10.17305\/bjbms.2022.7953","article-title":"PD-L1 testing by immunohistochemistry in immuno-oncology","volume":"23","author":"Vranic","year":"2023","journal-title":"Biomol. Biomed."},{"key":"ref_41","doi-asserted-by":"crossref","first-page":"508","DOI":"10.1016\/j.annonc.2024.03.007","article-title":"Tumor mutational burden for the prediction of PD-(L)1 blockade efficacy in cancer: Challenges and opportunities","volume":"35","author":"Wang","year":"2024","journal-title":"Ann. Oncol."},{"key":"ref_42","doi-asserted-by":"crossref","first-page":"3990","DOI":"10.1158\/1078-0432.CCR-20-4521","article-title":"Heterogeneity of IFN-Mediated Responses and Tumor Immunogenicity in Patients with Cervical Cancer Receiving Concurrent Chemoradiotherapy","volume":"27","author":"Chen","year":"2021","journal-title":"Clin. Cancer Res."},{"key":"ref_43","doi-asserted-by":"crossref","unstructured":"Reis, B., Attig, J., Dziadek, S., Graefe, N., Heller, A., Rieder, N., and Gomes, B. (2024). Tumor beta2-microglobulin and HLA-A expression is increased by immunotherapy and can predict response to CIT in association with other biomarkers. Front. Immunol., 15.","DOI":"10.3389\/fimmu.2024.1285049"},{"key":"ref_44","doi-asserted-by":"crossref","first-page":"1586","DOI":"10.1016\/j.cell.2018.07.009","article-title":"Generation of Tumor-Reactive T Cells by Co-culture of Peripheral Blood Lymphocytes and Tumor Organoids","volume":"174","author":"Dijkstra","year":"2018","journal-title":"Cell"},{"key":"ref_45","doi-asserted-by":"crossref","first-page":"961","DOI":"10.1084\/jem.191.6.961","article-title":"Multiple Genetic Alterations Cause Frequent and Heterogeneous Human Histocompatibility Leukocyte Antigen Class I Loss in Cervical Cancer","volume":"191","author":"Koopman","year":"2000","journal-title":"J. Exp. Med."},{"key":"ref_46","doi-asserted-by":"crossref","first-page":"533","DOI":"10.1074\/mcp.TIR117.000383","article-title":"High-throughput and Sensitive Immunopeptidomics Platform Reveals Profound Interferon\u03b3-Mediated Remodeling of the Human Leukocyte Antigen (HLA) Ligandome","volume":"17","author":"Chong","year":"2018","journal-title":"Mol. Cell. Proteom."},{"key":"ref_47","doi-asserted-by":"crossref","first-page":"426","DOI":"10.1016\/j.ygyno.2017.03.510","article-title":"T-cell target antigens across major gynecologic cancers","volume":"145","author":"Minutolo","year":"2017","journal-title":"Gynecol. Oncol."},{"key":"ref_48","doi-asserted-by":"crossref","first-page":"5562","DOI":"10.1158\/1078-0432.CCR-18-0573","article-title":"T-cell Responses to TP53 \u201cHotspot\u201d Mutations and Unique Neoantigens Expressed by Human Ovarian Cancers","volume":"24","author":"Deniger","year":"2018","journal-title":"Clin. Cancer Res."},{"key":"ref_49","doi-asserted-by":"crossref","first-page":"156","DOI":"10.1186\/s40425-019-0629-6","article-title":"Efficient identification of neoantigen-specific T-cell responses in advanced human ovarian cancer","volume":"7","author":"Liu","year":"2019","journal-title":"J. Immunother. Cancer"},{"key":"ref_50","doi-asserted-by":"crossref","first-page":"e010099","DOI":"10.1136\/jitc-2024-010099","article-title":"HERV-derived epitopes represent new targets for T-cell-based immunotherapies in ovarian cancer","volume":"13","author":"Bonaventura","year":"2025","journal-title":"J. Immunother. Cancer"},{"key":"ref_51","doi-asserted-by":"crossref","first-page":"e1065369","DOI":"10.1080\/2162402X.2015.1065369","article-title":"HLA ligandomics identifies histone deacetylase 1 as target for ovarian cancer immunotherapy","volume":"5","author":"Peper","year":"2016","journal-title":"OncoImmunology"},{"key":"ref_52","doi-asserted-by":"crossref","first-page":"2375","DOI":"10.1007\/s00262-023-03413-7","article-title":"Identification of antigenic epitopes recognized by tumor infiltrating lymphocytes in high grade serous ovarian cancer by multi-omics profiling of the auto-antigen repertoire","volume":"72","author":"Millar","year":"2023","journal-title":"Cancer Immunol. Immunother."},{"key":"ref_53","doi-asserted-by":"crossref","first-page":"115928","DOI":"10.1016\/j.biopha.2023.115928","article-title":"Personalized neoantigen-based T cell therapy triggers cytotoxic lymphocytes expressing polyclonal TCR against metastatic ovarian cancer","volume":"169","author":"Hung","year":"2023","journal-title":"Biomed. Pharmacother."},{"key":"ref_54","doi-asserted-by":"crossref","unstructured":"Van Amerongen, R.A., Tuit, S., Wouters, A.K., Van De Meent, M., Siekman, S.L., Meeuwsen, M.H., Wachsmann, T.L.A., Remst, D.F.G., Hagedoorn, R.S., and van der Steen, D.M. (2023). PRAME and CTCFL-reactive TCRs for the treatment of ovarian cancer. Front. Immunol., 14.","DOI":"10.3389\/fimmu.2023.1121973"},{"key":"ref_55","doi-asserted-by":"crossref","first-page":"e1267095","DOI":"10.1080\/2162402X.2016.1267095","article-title":"Impact of (chemo)radiotherapy on immune cell composition and function in cervical cancer patients","volume":"6","author":"Nout","year":"2017","journal-title":"OncoImmunology"},{"key":"ref_56","doi-asserted-by":"crossref","first-page":"991","DOI":"10.1042\/EBC20230001","article-title":"The role of IFN-\u03b3-signalling in response to immune checkpoint blockade therapy","volume":"67","author":"Wong","year":"2023","journal-title":"Essays Biochem."},{"key":"ref_57","doi-asserted-by":"crossref","first-page":"1420","DOI":"10.1158\/2159-8290.CD-17-0593","article-title":"Impaired HLA Class I Antigen Processing and Presentation as a Mechanism of Acquired Resistance to Immune Checkpoint Inhibitors in Lung Cancer","volume":"7","author":"Gettinger","year":"2017","journal-title":"Cancer Discov."},{"key":"ref_58","doi-asserted-by":"crossref","first-page":"819","DOI":"10.1056\/NEJMoa1604958","article-title":"Mutations Associated with Acquired Resistance to PD-1 Blockade in Melanoma","volume":"375","author":"Zaretsky","year":"2016","journal-title":"N. Engl. J. Med."},{"key":"ref_59","doi-asserted-by":"crossref","first-page":"1136","DOI":"10.1038\/s41467-017-01062-w","article-title":"Resistance to checkpoint blockade therapy through inactivation of antigen presentation","volume":"8","author":"Jiao","year":"2017","journal-title":"Nat. Commun."},{"key":"ref_60","doi-asserted-by":"crossref","first-page":"462","DOI":"10.1001\/jamaoncol.2021.5970","article-title":"Human Leukocyte Antigen Class I Antigen-Processing Machinery Upregulation by Anticancer Therapies in the Era of Checkpoint Inhibitors: A Review","volume":"8","author":"Sadagopan","year":"2022","journal-title":"JAMA Oncol."},{"key":"ref_61","doi-asserted-by":"crossref","first-page":"1642","DOI":"10.1158\/2326-6066.CIR-23-0139","article-title":"Antitumor Immune Responses in B2M-Deficient Cancers","volume":"11","author":"Torrejon","year":"2023","journal-title":"Cancer Immunol. Res."},{"key":"ref_62","doi-asserted-by":"crossref","first-page":"e1005507","DOI":"10.1080\/2162402X.2015.1005507","article-title":"HLA class I as a predictor of clinical prognosis and CTL infiltration as a predictor of chemosensitivity in ovarian cancer","volume":"4","author":"Hirohashi","year":"2015","journal-title":"OncoImmunology"},{"key":"ref_63","doi-asserted-by":"crossref","first-page":"44","DOI":"10.1038\/s41392-022-01264-9","article-title":"Single-cell RNA-sequencing reveals radiochemotherapy-induced innate immune activation and MHC-II upregulation in cervical cancer","volume":"8","author":"Liu","year":"2023","journal-title":"Signal Transduct. Target. Ther."},{"key":"ref_64","doi-asserted-by":"crossref","first-page":"2204951","DOI":"10.1002\/advs.202204951","article-title":"Single-Cell Landscape Highlights Heterogenous Microenvironment, Novel Immune Reaction Patterns, Potential Biomarkers and Unique Therapeutic Strategies of Cervical Squamous Carcinoma, Human Papillomavirus-Associated (HPVA) and Non-HPVA Adenocarcinoma","volume":"10","author":"Qiu","year":"2023","journal-title":"Adv. Sci."},{"key":"ref_65","doi-asserted-by":"crossref","first-page":"54","DOI":"10.1186\/s13046-024-02979-z","article-title":"LATS1\/2 loss promote tumor immune evasion in endometrial cancer through downregulating MHC-I expression","volume":"43","author":"Yang","year":"2024","journal-title":"J. Exp. Clin. Cancer Res."},{"key":"ref_66","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/s13048-018-0475-z","article-title":"Cancer-testis antigens in ovarian cancer: Implication for biomarkers and therapeutic targets","volume":"12","author":"Xie","year":"2019","journal-title":"J. Ovarian Res."},{"key":"ref_67","doi-asserted-by":"crossref","first-page":"202","DOI":"10.1038\/s41419-026-08429-2","article-title":"The long noncoding RNA AC093895.1 promotes ovarian cancer formation and metastasis through a positive feedback network dependent on the transcription factor SOX4","volume":"17","author":"Huang","year":"2026","journal-title":"Cell Death Dis."},{"key":"ref_68","doi-asserted-by":"crossref","first-page":"1860","DOI":"10.1038\/s41598-024-52413-9","article-title":"Network pharmacology combined with experimental verification to explore the potential mechanism of naringenin in the treatment of cervical cancer","volume":"14","author":"Zhou","year":"2024","journal-title":"Sci. Rep."},{"key":"ref_69","doi-asserted-by":"crossref","first-page":"846","DOI":"10.1016\/j.cell.2019.09.035","article-title":"Transcriptional Basis of Mouse and Human Dendritic Cell Heterogeneity","volume":"179","author":"Brown","year":"2019","journal-title":"Cell"},{"key":"ref_70","doi-asserted-by":"crossref","first-page":"1498","DOI":"10.1016\/j.ccell.2023.06.008","article-title":"A distinct stimulatory cDC1 subpopulation amplifies CD8+ T cell responses in tumors for protective anti-cancer immunity","volume":"41","author":"Meiser","year":"2023","journal-title":"Cancer Cell"},{"key":"ref_71","doi-asserted-by":"crossref","first-page":"200","DOI":"10.1038\/s41586-023-06299-8","article-title":"SLC38A2 and glutamine signalling in cDC1s dictate anti-tumour immunity","volume":"620","author":"Guo","year":"2023","journal-title":"Nature"},{"key":"ref_72","doi-asserted-by":"crossref","first-page":"240","DOI":"10.1038\/s43018-023-00668-y","article-title":"Cytokine-armed dendritic cell progenitors for antigen-agnostic cancer immunotherapy","volume":"5","author":"Ghasemi","year":"2024","journal-title":"Nat. Cancer"},{"key":"ref_73","doi-asserted-by":"crossref","first-page":"eadn9083","DOI":"10.1126\/science.adn9083","article-title":"In vivo dendritic cell reprogramming for cancer immunotherapy","volume":"386","author":"Ascic","year":"2024","journal-title":"Science"},{"key":"ref_74","doi-asserted-by":"crossref","first-page":"375","DOI":"10.1016\/j.cell.2023.12.011","article-title":"Bispecific dendritic-T cell engager potentiates anti-tumor immunity","volume":"187","author":"Barboy","year":"2024","journal-title":"Cell"},{"key":"ref_75","doi-asserted-by":"crossref","first-page":"15618","DOI":"10.1038\/ncomms15618","article-title":"DNA exonuclease Trex1 regulates radiotherapy-induced tumour immunogenicity","volume":"8","author":"Alard","year":"2017","journal-title":"Nat. Commun."},{"key":"ref_76","doi-asserted-by":"crossref","unstructured":"Chi, A., and Nguyen, N.P. (2023). Mechanistic rationales for combining immunotherapy with radiotherapy. Front. Immunol., 14.","DOI":"10.3389\/fimmu.2023.1125905"},{"key":"ref_77","doi-asserted-by":"crossref","first-page":"107","DOI":"10.1016\/j.immuni.2022.12.002","article-title":"CD8+ T cell activation in cancer comprises an initial activation phase in lymph nodes followed by effector differentiation within the tumor","volume":"56","author":"Prokhnevska","year":"2023","journal-title":"Immunity"},{"key":"ref_78","doi-asserted-by":"crossref","first-page":"116","DOI":"10.1038\/s41577-020-0390-6","article-title":"A few good peptides: MHC class I-based cancer immunosurveillance and immunoevasion","volume":"21","author":"Dersh","year":"2021","journal-title":"Nat. Rev. Immunol."}],"container-title":["Cells"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/2073-4409\/15\/19\/1809\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,10,5]],"date-time":"2026-10-05T08:12:17Z","timestamp":1791187937000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/2073-4409\/15\/19\/1809"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,10,3]]},"references-count":78,"journal-issue":{"issue":"19","published-online":{"date-parts":[[2026,10]]}},"alternative-id":["cells15191809"],"URL":"https:\/\/doi.org\/10.3390\/cells15191809","relation":{},"ISSN":["2073-4409"],"issn-type":[{"value":"2073-4409","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,10,3]]}}}